Altamira Therapeutics Ltd (NASDAQ: CYTO) stock jumped 180.28% on Friday to $0.28 against a previous-day closing price of $0.10. With 323.53 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4774 whereas the lowest price it dropped to was $0.1555. The 52-week range on CYTO shows that it touched its highest point at $6.31 and its lowest point at $0.09 during that stretch. It currently has a 1-year price target of $287.34. Beta for the stock currently stands at 1.63.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYTO was up-trending over the past week, with a rise of 162.91%, but this was up by 76.99% over a month. Three-month performance dropped to -22.16% while six-month performance fell -68.36%. The stock lost -95.18% in the past year, while it has lost -94.23% so far this year.
Float and Shares Shorts:
At present, 8.83 million CYTO shares are outstanding with a float of 8.78 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.18 million, which was 2.30% higher than short shares on Sep 28, 2023. In addition to Dr. Thomas Meyer Ph.D. as the firm’s Founder, Chairman, CEO & MD, Mr. Marcel Gremaud CPA serves as its Chief Financial Officer.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYTO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYTO analysts setting a high price target of $286.10 and a low target of $286.10, the average target price over the next 12 months is $286.10. Based on these targets, CYTO could surge 102078.57% to reach the target high and rise by 102078.57% to reach the target low. Reaching the average price target will result in a growth of 102078.57% from current levels.